Intercept Pharma (ICPT) Tops Q2 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 2, 2023 7:00 AM EDTOcaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarterCompany updates full-year 2023 Ocaliva net sales guidance to $320 million to $340 million; reiterates non-GAAP adjusted operating expense guidance of $350 million to $370 millionRestructuring plan is on track to reduce operating expenses by approximately $140 millionCompany expects to achieve meaningful profitability in 2024OCA-bezafibrate combination making considerable progress; enrollment of both Phase 2 studies completed; Company expects to have necessary data... More
